Kato S, Yokoyama T, Fujikawa T, Kirizuki Y, Mantani Y, Miki T
J Vet Med Sci. 2024; 86(3):300-307.
PMID: 38267037
PMC: 10963091.
DOI: 10.1292/jvms.23-0492.
Vansandt L, Meinsohn M, Godin P, Nagykery N, Sicher N, Kano M
Nat Commun. 2023; 14(1):3140.
PMID: 37280258
PMC: 10244415.
DOI: 10.1038/s41467-023-38721-0.
Li Y, Wei L, Meinsohn M, Suliman R, Chauvin M, Berstler J
Proc Natl Acad Sci U S A. 2022; 119(15):e2122512119.
PMID: 35380904
PMC: 9169708.
DOI: 10.1073/pnas.2122512119.
Hart K, Stocker W, Nagykery N, Walton K, Harrison C, Donahoe P
Proc Natl Acad Sci U S A. 2021; 118(26).
PMID: 34155118
PMC: 8256043.
DOI: 10.1073/pnas.2104809118.
Ferguson J, Pepin D, Duru C, Matejtschuk P, Donahoe P, Burns C
Reprod Biomed Online. 2018; 37(5):631-640.
PMID: 30241771
PMC: 6302068.
DOI: 10.1016/j.rbmo.2018.08.012.
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Pepin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K
Proc Natl Acad Sci U S A. 2015; 112(32):E4418-27.
PMID: 26216943
PMC: 4538667.
DOI: 10.1073/pnas.1510604112.
An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance.
Pepin D, Hoang M, Nicolaou F, Hendren K, Benedict L, Al-Moujahed A
Technology. 2014; 1(1):63-71.
PMID: 24729676
PMC: 3980489.
DOI: 10.1142/S2339547813500076.
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.
Chang H, Pieretti-Vanmarcke R, Nicolaou F, Li X, Wei X, MacLaughlin D
Gynecol Oncol. 2010; 120(1):128-34.
PMID: 21056908
PMC: 3008816.
DOI: 10.1016/j.ygyno.2010.09.017.
Focal Mullerian duct retention in male mice with constitutively activated beta-catenin expression in the Mullerian duct mesenchyme.
Tanwar P, Zhang L, Tanaka Y, Taketo M, Donahoe P, Teixeira J
Proc Natl Acad Sci U S A. 2010; 107(37):16142-7.
PMID: 20805501
PMC: 2941287.
DOI: 10.1073/pnas.1011606107.
Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.
Papakostas T, Pieretti-Vanmarcke R, Nicolaou F, Thanos A, Trichonas G, Koufomichali X
Protein Expr Purif. 2009; 70(1):32-8.
PMID: 19755162
PMC: 3581853.
DOI: 10.1016/j.pep.2009.09.004.
Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct.
Fujino A, Arango N, Zhan Y, Manganaro T, Li X, MacLaughlin D
Dev Biol. 2008; 325(2):351-62.
PMID: 19013450
PMC: 3935311.
DOI: 10.1016/j.ydbio.2008.10.027.
A single base pair mutation encoding a premature stop codon in the MIS type II receptor is responsible for canine persistent Müllerian duct syndrome.
Wu X, Wan S, Pujar S, Haskins M, Schlafer D, Lee M
J Androl. 2008; 30(1):46-56.
PMID: 18723470
PMC: 2593750.
DOI: 10.2164/jandrol.108.005736.
c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.
Renlund N, Pieretti-Vanmarcke R, ONeill F, Zhang L, Donahoe P, Teixeira J
Endocrinology. 2007; 149(1):108-15.
PMID: 17947357
PMC: 2194615.
DOI: 10.1210/en.2007-0529.
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Pieretti-Vanmarcke R, Donahoe P, Pearsall L, Dinulescu D, Connolly D, Halpern E
Proc Natl Acad Sci U S A. 2006; 103(46):17426-31.
PMID: 17088539
PMC: 1859945.
DOI: 10.1073/pnas.0607959103.
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.
Szotek P, Pieretti-Vanmarcke R, Masiakos P, Dinulescu D, Connolly D, Foster R
Proc Natl Acad Sci U S A. 2006; 103(30):11154-9.
PMID: 16849428
PMC: 1544057.
DOI: 10.1073/pnas.0603672103.
Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents.
Trbovich A, Sluss P, Laurich V, ONeill F, MacLaughlin D, Donahoe P
Proc Natl Acad Sci U S A. 2001; 98(6):3393-7.
PMID: 11248089
PMC: 30664.
DOI: 10.1073/pnas.051632298.
Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.
Stephen A, Masiakos P, Segev D, Vacanti J, Donahoe P, MacLaughlin D
Proc Natl Acad Sci U S A. 2001; 98(6):3214-9.
PMID: 11248058
PMC: 30633.
DOI: 10.1073/pnas.051625998.
Molecular differentiation of the mouse genital tract: serum-free organ culture system for morphological and biochemical correlations.
Newbold R, CARTER D, Harris S, McLachlan J
In Vitro. 1981; 17(1):51-4.
PMID: 7216239
DOI: 10.1007/BF02618030.
Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice.
Donahoe P, Fuller Jr A, Scully R, Guy S, Budzik G
Ann Surg. 1981; 194(4):472-80.
PMID: 6895157
PMC: 1345325.
DOI: 10.1097/00000658-198110000-00010.
Dissociation between testicular organogenesis and endocrine cytodifferentiation of Sertoli cells.
Magre S, Jost A
Proc Natl Acad Sci U S A. 1984; 81(24):7831-4.
PMID: 6595663
PMC: 392246.
DOI: 10.1073/pnas.81.24.7831.
